Potential use of statins in the treatment of antiphospholipid syndrome

Current Rheumatology Reports

Volumn 14, Issue 1, 2012, Pages 87-94

  Lopez Pedrera, Chary ^a   Ruiz Limon, Patricia ^a   Aguirre, M Angeles ^a   Rodriguez Ariza, Antonio ^a   Cuadrado, Maria José ^a  

^a Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

Author keywords

Antiphospholipid syndrome; Proteomic approaches; Statins; Thrombosis; Treatment

Indexed keywords

ATORVASTATIN; CATHEPSIN D; FLUINDOSTATIN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; JANUS KINASE; LIPOCORTIN 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PRAVASTATIN; PROTEIN DISULFIDE ISOMERASE; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ACE GENE; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; APOE GENE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CD36 GENE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CETP GENE; CLINICAL ASSESSMENT TOOL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; ENDOTHELIUM CELL; ESR1 GENE; FGB GENE; GENE PRODUCT; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GPIIIA GENE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LIPOPHILICITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MMP3 GENE; MONOCYTE; OUTCOME ASSESSMENT; PATHOGENESIS; PHARMACOGENOMICS; PLEIOTROPY; PROTEOMICS; SLE DISEASE ACTIVITY INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS; TH2 CELL; THROMBOSIS; VASCULARIZATION;

ANTIPHOSPHOLIPID SYNDROME; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84856930436     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0222-6     Document Type: Article

References (66)

1. G Espinosa R Cervera J Font Y Shoenfeld 2003 Antiphospholipid syndrome: pathogenic mechanisms Autoimmun Rev 2 86 93 12848964 10.1016/S1568-9972(02) 00144-1 (Pubitemid 37443860)
2. T Koike M Bohgaki O Amengual T Atsumi 2007 Antiphospholipid antibodies, Lessons from the bench J Autoimmun 28 129 33 17383159 10.1016/j.jaut.2007.02.009 1:CAS:528:DC%2BD2sXkvFOls70%3D (Pubitemid 46670690)
3. MJ Cuadrado C Lopez-Pedrera MA Khamashta, et al. 1997 Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression Arthritis Rheum 40 834 41 9153543 10.1002/art.1780400509 1:CAS:528:DyaK2sXjsV2hs7Y%3D (Pubitemid 27199998)
4. PM Dobado-Berrios Ch Lopez-Pedrera F Velasco, et al. 1999 Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome Thromb Haemost 82 1578 82 10613637 1:CAS:528:DyaK1MXotVehsb0%3D
5. PM Dobado-Berrios Ch Lopez-Pedrera F Velasco MJ Cuadrado 2001 The role of TF in the antiphospholipid syndrome Arthritis Rheum 44 2467 76 11710702 10.1002/1529-0131(200111)44:11<2467::AID-ART426>3.0.CO;2-U 1:CAS:528:DC%2BD38Xps1E%3D (Pubitemid 33049324)
6. Ch López-Pedrera P Buendía MJ Cuadrado, et al. 2006 Antiphospholipid antibodies from antiphospholipid syndrome patients induce monocyte expression through the simultaneous activation of both NFkB/Rel proteins via p38 MAPK pathway, and the MEK1/ERK pathway Arthritis Rheum 54 301 11 16385547 10.1002/art.21549 (Pubitemid 43122214)
7. M Vega-Ostertag EN Harris SS Pierangeli 2004 Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin Arthritis Rheum 50 2911 9 15457460 10.1002/art.20434 1:CAS:528:DC%2BD2cXoslGgsb4%3D (Pubitemid 39209530)
8. M Bohgaki T Atsumi Y Yamashita, et al. 2004 The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2glycoprotein I antibodies Int Immunol 16 1633 41 15466912 10.1093/intimm/dxh166 1:CAS:528: DC%2BD2cXos1Wqtbc%3D (Pubitemid 39480782)
9. G Montiel-Manzano Z Romay-Penabad 2007 Papalardo de Martinez E, et al.: In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies Ann N Y Acad Sci 1108 540 53 17894019 10.1196/annals.1422.057 1:CAS:528:DC%2BD2sXhtVSqtrvM (Pubitemid 47528768)
10. S Dunoyer-Geindre P de Moerloose 2002 Galve-de Rochemonteix B, et al.: NFkappa B is an essential intermediate in the activation of endothelial cells by anti-beta(2)- glycoprotein 1 antibodies Thromb Haemost 88 851 7 12428105 (Pubitemid 35345346)
11. M Vega-Ostertag K Casper R Swerlick, et al. 2005 Involvement of p38 MAPK in the upregulation of tissue factor on endothelial cells by antiphospholipid antibodies Arthritis Rheum 52 1545 54 15880836 10.1002/art.21009 1:CAS:528:DC%2BD2MXkvFCisrg%3D (Pubitemid 40663946)
12. HF Dvorak 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 4368 80 12409337 10.1200/JCO.2002.10.088 1:CAS:528:DC%2BD38Xpt1CjtL0%3D (Pubitemid 35266299)
13. FMK Williams K Parmar GRV Hughes BJ Hunt 2000 Systemic endothelial cell markers in primary antiphospholipid syndrome Thromb Haemost 84 742 6 11127848 1:CAS:528:DC%2BD3cXovFCjs74%3D
14. MJ Cuadrado P Buendía F Velasco, et al. 2006 Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome J Thromb Haemost 4 2461 9 16968331 10.1111/j.1538-7836.2006.02193.x 1:CAS:528:DC%2BD28Xht1yjtbbJ (Pubitemid 44575442)
15. J George D Harats B Gilburd, et al. 1999 Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression Circulation 99 2227 30 10226085 1:CAS:528:DyaK1MXjtFKku7s%3D (Pubitemid 29201126)
16. Y Shoenfeld Y Sherer J George D Harats 2000 Autoantibodies associated with atherosclerosis Ann Med 32 37 40 11209980 1:CAS:528:DC%2BD3MXivV2ksLc%3D (Pubitemid 32115806)
17. K Veres G Lakos A Kerenyi, et al. 2004 Antiphospholipid antibodies in acute coronary syndrome Lupus 13 423 7 15303568 10.1191/0961203304lu1011oa 1:CAS:528:DC%2BD2cXmvFWisLY%3D (Pubitemid 38931773)
18. LJ Jara G Medina O Vera-Lastra 2007 Systemic antiphospholipid síndrome and atherosclerosis Clin Rev Allergy Immunol 32 172 7 17916989 10.1007/s12016-007-0008-9 1:CAS:528:DC%2BD2sXht1yktrrJ (Pubitemid 47571442)
19. SS Pierangeli G Girardi M Vega-Ostertag, et al. 2005 Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia Arthritis Rheum 52 2120 4 15986360 10.1002/art.21157 1:CAS:528:DC%2BD2MXnsl2gt7w%3D (Pubitemid 40994335)
20. G Girardi P Redecha JE Salmon 2004 Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation Nat Med 10 1222 6 15489858 10.1038/nm1121 1:CAS:528:DC%2BD2cXptVOgsbc%3D (Pubitemid 39540439)
21. SS Pierangeli PP Chen E Raschi, et al. 2008 Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms Semin Thromb Hemost 34 236 50 18720303 10.1055/s-0028-1082267 1:CAS:528:DC%2BD1MXnvF2gur8%3D
22. S Stone MA Khamashta L Poston 2001 Placentation, antiphospholipid syndrome and pregnancy outcome Lupus 10 67 74 11237128 10.1191/ 096120301667486047 1:CAS:528:DC%2BD3MXjsV2kur0%3D (Pubitemid 32410088)
23. N Di Simone MP Luigi D Marco, et al. 2007 Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature Ann N Y Acad Sci 1108 505 14 17894016 10.1196/annals.1422.054 (Pubitemid 47528765)
24. LW Chamley JL Allen PM Johnson 1997 Synthesis of beta2 glycoprotein 1 by the human placenta Placenta 18 403 10 9250702 10.1016/S0143-4004(97)80040-9 1:CAS:528:DyaK2sXls1egtbk%3D (Pubitemid 27326309)
25. N Di Simone E Raschi C Testoni, et al. 2005 Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro Ann Rheum Dis 64 462 7 15256379 10.1136/ard.2004.021444 (Pubitemid 40283060)
26. MJ Mulla JJ Brosens LW Chamley, et al. 2009 Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway Am J Reprod Immunol 62 96 111 19614626 10.1111/j.1600-0897. 2009.00717.x 1:CAS:528:DC%2BD1MXhtVeisLfK
27. G Ruiz-Irastorza M Crowther W Branch MA Khamashta 2010 Antiphospholipid syndrome Lancet 376 1498 509 20822807 10.1016/S0140-6736(10)60709-X 1:CAS:528:DC%2BC3cXhtlKjs7bJ This is an elegant revision centered on the recent suggestions for therapy of thrombosis as well as obstetric care in APS patients, including a perspective on the future use of therapies such as hydroxychloroquine, statins, rituximab, and new anticoagulant drugs
28. M Cortellaro E Cofrancesco E Arbustini, et al. 2002 Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study Thromb Haemost 88 41 7 12152675 1:CAS:528:DC%2BD38XlslKmtLg%3D (Pubitemid 34752265)
29. PM Ridker E Danielson FA Fonseca, et al. 2009 JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 1175 82 19329177 10.1016/S0140-6736(09)60447-5 1:CAS:528: DC%2BD1MXktV2gsL8%3D
30. RJ Glynn E Danielson FA Fonseca, et al. 2009 A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 1851 61 19329822 10.1056/NEJMoa0900241 1:CAS:528:DC%2BD1MXlsVSlurk%3D
31. J Greenwood L Steinman SS Zamvil 2006 Statin therapy and autoimmune disease: from protein prenylation to immunomodulation Nat Rev Immunol 6 358 70 16639429 10.1038/nri1839 1:CAS:528:DC%2BD28XjslOhu7Y%3D
32. JK Liao U Laufs 2005 Pleiotropic effects of statins Annu Rev Pharmacol Toxicol 45 89 118 15822172 10.1146/annurev.pharmtox.45.120403.095748 1:CAS:528:DC%2BD2MXisVWjtrY%3D (Pubitemid 40261799)
33. A Undas E Brummel-Ziedins KG Mann 2005 Statins and blood coagulation Arterioscler Thromb Vasc Biol 25 1 8 10.1161/01.ATV.0000168913.25278.38 (Pubitemid 40923379)
34. HF Kuipers PJ Biesta TA Groothuis, et al. 2005 Statins affect T cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains Hum Immunol 66 653 65 15993711 10.1016/j.humimm.2005.04.004 1:CAS:528:DC%2BD2MXlvFansbY%3D (Pubitemid 40922554)
35. R Ghittoni L Patrussi K Pirozzi, et al. 2005 Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases FASEB J 19 605 7 15677697 1:CAS:528:DC%2BD2MXjtFaks74%3D (Pubitemid 40471259)
36. SE Dunn S Youssef MJ Goldstein, et al. 2006 Isoprenoids determine Th1/Th2 fate in pathogenic T cells providing a mechanism of modulation of autoimmunity by atorvastatin J Exp Med 203 401 12 16476765 10.1084/jem.20051129 1:CAS:528:DC%2BD28XhslClt70%3D (Pubitemid 43290849)
37. J Greenwood CE Walters G Pryce, et al. 2003 Lovastatin inhibits brain endothelial Rho-dependent lymphocyte migration and attenuates experimental autoimmune encephalomyelitis FASEB J 17 905 7 12626426 1:CAS:528: DC%2BD3sXjsFantbw%3D
38. M Yoshida T Sawada H Ishii, et al. 2001 HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism Arterioscler Thromb Vasc Biol 21 1165 71 11451746 10.1161/hq0701.092143 1:CAS:528: DC%2BD3MXltlKmtrc%3D (Pubitemid 34215145)
39. A Rezaie-Majd GW Prager RA Bucek, et al. 2003 Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients Arterioscler Thromb Vasc Biol 23 397 403 12615677 10.1161/01.ATV.0000059384.34874.F0 1:CAS:528:DC%2BD3sXhslWhsb4%3D (Pubitemid 36337214)
40. NA Turner DJ O'Regan SG Ball KE Porter 2005 Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels FASEB J 19 804 6 15728660 1:CAS:528:DC%2BD2MXktVKmsbw%3D (Pubitemid 40617390)
41. SO Youssef JC Stuve PJ Patarroyo, et al. 2002 The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 78 84 12422218 10.1038/nature01158 1:CAS:528:DC%2BD38XosVCmu7Y%3D (Pubitemid 35291443)
42. X Zhang J Jin X Peng VS Ramgolam S Markovic-Plese 2008 Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes J Immunol 180 6988 96 18453621 1:CAS:528:DC%2BD1cXltlCrs78%3D
43. DI Chasman D Posada L Subrahmanyan, et al. 2004 Pharmacogenetic study of statin therapy and cholesterol reduction JAMA 291 2821 7 15199031 10.1001/jama.291.23.2821 1:CAS:528:DC%2BD2cXkvFKnsLY%3D (Pubitemid 38747801)
44. G Siest JB Marteau S Maumus, et al. 2005 Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers Eur J Pharmacol 527 1 22 16316654 10.1016/j.ejphar.2005.10.011 1:CAS:528:DC%2BD2MXht1OltbfL (Pubitemid 41745146)
45. MC Duran JL Martin-Ventura S Mohammed, et al. 2007 Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques Eur J Pharmacol 562 119 29 17336287 10.1016/j.ejphar.2007.01.077 1:CAS:528: DC%2BD2sXjslSksbw%3D (Pubitemid 46466765)
46. DE Grobbee ML Bots 2004 Atherosclerotic disease regression with statins: studies using vascular markers Int J Cardiol 96 447 59 15301899 10.1016/j.ijcard.2004.01.005 (Pubitemid 39099508)
47. NG Anderson NL Anderson 1996 Twenty years of two-dimensional electrophoresis: past, present and future Electrophoresis 17 443 53 8740157 10.1002/elps.1150170303 1:CAS:528:DyaK28Xis1Siur0%3D (Pubitemid 26126779)
48. A Undas M Celiska-Lowenhoff M Kaczor J Musial 2004 New nonlipid effects of statins and their clinical relevance in cardiovascular disease Thromb Haemost 91 1065 77 15175791 1:CAS:528:DC%2BD2cXltFyqu70%3D (Pubitemid 38821261)
49. R Krysiak B Okopien ZS Herman 2003 Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes Drugs 63 1821 54 12921488 10.2165/00003495-200363170-00005 1:CAS:528:DC%2BD3sXnvFeisLY%3D (Pubitemid 37083030)
50. PL Meroni E Raschi C Testoni, et al. 2001 Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype Arthritis Rheum 44 2870 8 11762948 10.1002/1529-0131(200112)44:12<2870::AID- ART475>3.0.CO;2-Y 1:CAS:528:DC%2BD38XislCltQ%3D%3D (Pubitemid 34016207)
51. DE Ferrara X Liu RG Espinola, et al. 2003 Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model Arthritis Rheum 48 3272 9 14613293 10.1002/art.11449 1:CAS:528:DC%2BD3sXpvVygtbk%3D (Pubitemid 37409342)
52. DE Ferrara R Swerlick K Casper, et al. 2004 Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells J Thromb Haemost 2 1558 63 15333031 10.1111/j.1538-7836.2004. 00896.x 1:CAS:528:DC%2BD2cXosF2rtLg%3D (Pubitemid 40186171)
53. LA Martínez MC Amigo A Orozco, et al. 2007 Effect of rosuvastatin on VCAM-1 expression by HUVEC exposed to APS serum in an in vitro model Clin Exp Rheumatol 25 18 9
54. C López-Pedrera P Ruiz-Limón MA Aguirre, et al. 2011 Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome Ann Rheum Dis 70 675 82 21173016 10.1136/ard.2010. 135525 This study delineates the cellular and molecular mechanisms of action of fluvastatin on monocytes from APS patients through both an in vivo study and a confirmatory in vitro study
55. P Redecha CW Franzke W Ruf, et al. 2008 Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates foetal death in a mouse model of antiphospholipid syndrome J Clin Invest 118 3453 61 18802482 1:CAS:528:DC%2BD1cXht1ChsrjK
56. P Redecha N van Rooijen D Torry G Girardi 2009 Pravastatin prevents miscarriages in mice: role of tissue factor in placental and foetal injury Blood 113 4101 9 19234141 10.1182/blood-2008-12-194258 1:CAS:528:DC%2BD1MXlsVWrtrg%3D
57. P Jajoria V Murthy E Papalardo, et al. 2009 Statins for the treatment of antiphospholipid syndrome? Ann NY Acad Sci 1173 736 45 19758223 10.1111/j.1749-6632.2009.04815.x 1:CAS:528:DC%2BD1MXhtlCnt73I This study examined whether fluvastatin affects the plasma levels of various proinflammatory/prothrombotic markers in APS patients. The authors found that fluvastatin significantly reduced those markers in the majority of treated patients. The data from this study show that statins may be beneficial in aPL-positive patients
58. PM Ridker E Danielson FA Fonseca 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 20 2195 207 10.1056/NEJMoa0807646
59. I Kenis S Tartakover-Matalon N Cherepnin, et al. 2005 Simvastatin has deleterious effects on human first trimester placental explants Hum Reprod 20 2866 72 15958395 10.1093/humrep/dei120 1:CAS:528:DC%2BD2MXhtVelsLbN (Pubitemid 41487645)
60. K Forbes LM Hurst JD Aplin M Westwood JM Gibson 2008 Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisable J Cell Mol Med 12 2295 6 19120704 10.1111/j.1582-4934.2008.00466.x
61. J Ponce NP de La Ossa O Hurtado, et al. 2008 Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol mediated effect in neuroprotection Stroke 39 1269 75 18323503 10.1161/STROKEAHA.107.498923 1:CAS:528:DC%2BD1cXjtlSqtro%3D (Pubitemid 351440701)
62. J Ding D Jiang M Kurczy, et al. 2008 Inhibition of HMG CoA reductase reveals an unexpected role for cholesterol during PGC migration in the mouse BMC Dev Biol 8 120 19117526 10.1186/1471-213X-8-120
63. GA Ferreira TP Navarro RW Telles, et al. 2007 Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial Rheumatology 46 1560 5 17693444 10.1093/rheumatology/kem186 1:CAS:528:DC%2BD2sXhsVWgsLrM (Pubitemid 47500570)
64. PJ Kotyla B Sliwinska-Kotyla EJ Kucharz 2006 TNF-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin J Rheumatol 33 2361 3 17086617 (Pubitemid 44749805)
65. KL Graham LY Lee JP Higgins L Steinman PJ Utz PP Ho 2008 Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus Arthritis and Rheumatism 58 2098 104 18576356 10.1002/art.23605 1:CAS:528:DC%2BD1cXpt1Wku7Y%3D (Pubitemid 351988101)
66. GE Norby I Holme B Fellström, et al. 2009 Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus a randomized placebo controlled study Arthritis Rheumatism 60 1060 4 19333947 10.1002/art.24379 1:CAS:528:DC%2BD1MXltFemsr4%3D